Autologous bone marrow transplantation in the treatment of breast cancer: clinical and technologic strategies.
Autologous bone marrow transplantation has permitted the clinical investigation of dose-intense chemotherapy for solid tumors as well as hematologic malignancies. The most widely studied solid tumor is breast cancer, the most common malignant disease cause of death in women under the age of 55 years in the United States. Promising results in terms of disease-free, chemotherapy-free survival have been achieved for patients with low-dose chemotherapy-sensitive metastatic disease. Issues such as the selection of drugs to be used in combination chemotherapy for both the induction phase and the high-dose therapy phase, the timing of high-dose therapy, the role of peripheral stem cells, and marrow purging remain under intensive investigation. The rational extension of this strategy into the adjuvant and neoadjuvant settings is also under study.
Vaughan
W P
WP
Division of Hematology/Oncology, University of Alabama at Birmingham 35294.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans
D000970:Antineoplastic Agents